Imatinib and Norvasc (Amlodipine) (Norvasc 5 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Imatinib may increase exposure to a CYP3A-metabolized dihydropyridine calcium-channel blocker.
Clinical significance and safety
Norvasc 5 mg contains a dihydropyridine calcium-channel blocker. GLEEVEC identifies this class among medicines whose concentrations can rise with imatinib. Blood pressure, dizziness and tolerability should be reviewed; cardiovascular therapy should not be adjusted independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.